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Highlights 
 High levels of serum Vitamin D seems to protect against breast cancer risk. 
 The protective effect seems to be stronger for triple negative tumors 
 No differences were observed by menopausal status, TNM staging or main risk factors 
 Similar results were observed using cases sampled in the 1st month after diagnosis. 
Abstract 
Epidemiologic evidence on the association between vitamin D and breast cancer is still 
inconclusive. This study analyzes the association between serum 25-hydroxyvitamin D 
(25(OH)D) and breast cancer risk by pathologic subtype, stage at diagnosis and specific breast 
cancer risk factors. We conducted a population-based multicase-control study where 546 
histologically-confirmed breast cancer cases and 558 population controls, frequently matched by 
geographic area, age and body mass index, were recruited in 12 Spanish provinces (MCC-Spain). 
Information was collected by a questionnaire and plasma 25(OH)D was measured by solid-phase 
extraction on-line coupled to liquid chromatography–tandem mass spectrometry (SPE–LC–
MS/MS). Odds ratios and 95% confidence intervals were calculated using logistic and 
multinomial mixed regression models. We found a clear protective effect between 25(OH)D 
levels and breast cancer risk, with a significant dose-response trend (OR per 10 nmol/L= 0.88; 
95%CI= 0.82-0.94). While no differences were observed between pre and postmenopausal 
women, stage at diagnosis, or across strata of the main breast cancer risk factors, the protection 
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was more pronounced for triple negative tumors (OR per 10 nmol/L= 0.64; p-
heterogeneity=0.038). Similar results were observed when only cases sampled in the first month 
after diagnosis were considered. The protective effect of vitamin D on breast cancer risk may be 
subtype specific, being stronger for more aggressive tumors, which provides a new approach to 
prevent this disease. 
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; N, number of participants in each group; P25-
P75,  percentil 25 and percentil 75 of the mean 25(OH)D concentration. 
 
Keywords: 25(OH)D; Vitamin D; Calcidiol; Breast neoplasm; Triple negative tumor; Stage at 
diagnosis 
1. Introduction 
Vitamin D is known as the “sunshine” vitamin, because sun exposure is by far the main source of this nutrient 
in humans. Vitamin D is the precursor to the steroid hormone calcitriol (1,25-dihydroxy-vitamin D), required 
to absorb and maintain calcium concentrations within the physiological range, and its deficiency causes rickets, 
osteomalacia and osteoporosis [1, 2]. Inside the body, vitamin D suffers a first hydroxylation in the liver and 
the serum concentration of the resulting 25-hydroxy-vitamin D (25(OH)D) is considered the main biomarker 
reflecting vitamin D status. A second hydroxylation in the kidney is required to transform 25(OH)D into 
calcitriol [1]. During the last decade, vitamin D has attracted a lot of attention due to its role in multiple 
signaling pathways involved in proliferation, apoptosis, differentiation, inflammation, invasion, angiogenesis 
and metastasis [3]. Calcitriol functions activating the vitamin D nuclear receptor (VDR) present in most cells 
in the body. In this way, calcitriol regulates as much as 3-5% of the human genome [1]. In fact, multiple 
laboratory studies support a role for vitamin D in retarding cancer development and progression [3].  
There is no unanimous consensus on optimal levels of 25(OH)D. While the Institute of Medicine in the US 
established a cutoff of  50 nmol/L (20 ng/mL) [4], the US Endocrine Society considered that concentrations 
between 20-29 ng/mL indicate a relative insufficiency and set up a cutoff of 75 nmol/L (30 ng/mL) [5]. Using 
this definition, it has been estimated that Vitamin D insufficiency affects almost 50% of the population 
worldwide [6]. In Spain, despite favorable climatology, the levels are similar to, or even lower than, those 
described for Europe. These lower levels may be owing to more skin pigmentation, sunshine-avoiding 
AC
CE
PT
ED
 M
AN
US
CR
IPT
behavior, use of UV protection cream and air pollution with ozone and nitrogen dioxide, which reduce sun-
induced vitamin D production [7, 8]. 
In 2008, a review by the International Agency for Research on Cancer concluded that observational studies 
regarding vitamin D and colorectal cancer give conclusive evidence of a protective effect, while studies linking 
vitamin D and breast cancer were more heterogeneous [9]. Since then, different meta-analyses have been 
published, generally reflecting an inverse relationship between 25(OH)D and breast cancer [10-13], more 
consistent in case-control than in cohort studies. Moreover, there is little information regarding the association 
of vitamin D status and breast cancer subtypes. 
This paper examines the association between serum 25(OH)D and breast cancer risk, the dose-response shape 
of this relationship and  possible differences in this association by menopausal status, pathologic subtype and 
stage at diagnosis in a subsample of untreated breast cancer cases and population-based controls from a large 
case-control study in Spain (MCC-Spain).  
2. Materials and Methods 
2.1. Study Population 
MCC-Spain is a population-based multicase-control study conducted between 2008 and 2013 in 12 
geographical areas in Spain, to identify environmental factors associated with malignant tumors with high 
incidence -breast cancer included- and/or presenting specific characteristics in our country 
(http://www.mccspain.org). The study design has been extensively described elsewhere [14]. Briefly, the study 
recruited more than 6000 patients 20-85 years old with histologically confirmed incident tumors (including 
1738 breast cancer cases), and a single set of 4101 population controls (including 2038 women, 1910 suitable 
as breast cancer controls). Response rates were 69% for breast cancer cases and 54% among their controls 
[15]. Participants were interviewed by trained personnel using a computer-assisted program, gathering 
information on sociodemographic, life-style, reproductive history, hormonal factors, medications and personal 
and family medical history. Participants received a validated Food Frequency Questionnaire (FFQ) referred to 
the 12 months previous to diagnosis (cases) or recruitment (controls). This questionnaire was completed at 
home and mailed to recruiting centers (response rate of 89.9% for cases and 90.2 for controls). Blood samples 
were collected from 76% of participants. The study was approved by the Ethics Committees of the participating 
institutions and all participants signed an informed consent form.   
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For this study, we selected those breast cancer cases who had donated a blood sample before starting 
chemotherapy, radiotherapy or hormonotherapy (546 cases).  Based on pathology records, the cases were 
classified into three groups, using a simplified version of the St Gallen international consensus [16]: 1) estrogen 
receptor positive (ER+) and/or progesterone receptor positive (PR+) without overexpression of the human 
epidermal growth factor receptor 2 (HER2), 2) HER2 positive tumors (HER2+), and 3) triple negative (ER-, 
PR- and HER2-) tumors. Regarding stage at diagnosis, we considered stage I, stage II and stages III & IV. The 
last two were included in a single category, due to the small number of women showing metastasis at diagnosis 
(16 women).  
Cases and controls were frequency matched on geographic area, age (5-year groups) and body mass index 
(BMI) (5-unit groups) (n=558).  
2.2. Biochemical Analyses 
Details of the method for determination of 25(OH)D have been described elsewhere [17]. In brief, an on-line 
arrangement of automatic solid-phase extraction–liquid chromatography–tandem mass spectrometry (SPE–
LC–MS/MS) was used, in which 200 µL of filtered serum spiked with the deuterated standards of the analytes 
was introduced for cleanup–chromatographic separation as required–tandem mass spectrometry detection. 
Quantitation was carried out using calibration models with the ratio between the area of the chromatographic 
peak from each analyte and that of the corresponding deuterated standard. 
2.3. Statistical Methods 
For descriptive purposes, characteristics of cases and controls were summarized as percentages and mean 
values, and compared using chi-square and t-tests. Differences in the concentration of 25(OH)D according to 
these characteristics were checked out in the control population (t-test and ANOVA tests). The association 
between 25(OH)D and breast cancer was studied using mixed logistic regression models, considering the 
geographical area as a random effect term (included in all multivariate analyses). Four logistic models with 
increasing degrees of adjustment were fitted: Model 1 only adjusted for the matching variables: age and BMI. 
Model 2 adds menopausal status and the day when the sample was extracted. This variable was included using 
natural splines, to take into account the non-linear variation of vitamin D levels throughout the year. Model 
3a, further adjusted for educational level, ethnicity, age at first full term delivery (with a category of 
nulliparous), family history of breast cancer, personal history (previous breast biopsies, hypercholesterolemia 
and hormone replacement therapy (HRT) use), skin color, and physical activity in the last 5 years (MET-
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h/week). Finally, a sensitivity analysis (model 3b) was fitted further adjusting for total energy intake, calcium 
and alcohol intake using cases and controls who completed the FFQ. All these models were fitted with 
25(OH)D concentration (nmol/L) categorized into 5 levels, according to the quintiles in the control group, and 
as a continuous variable. The shape of the dose-response relationship was investigated using natural splines 
with 5 nodes at percentiles 5, 27.5, 50, 72.5 and 95. 
Differences in the effect of 25(OH)D according to menopausal status and breast cancer subtype were explored 
considering both a 3-category variable, based on controls’ tertiles, and the continuous variable. For menopausal 
status, differences in pre- and postmenopausal women were tested including in the final model the 
corresponding interaction term. For breast cancer subtypes, we fitted multinomial logistic regression models 
adjusting for the same factors. Heterogeneity of effects was tested comparing the coefficients (linear effect) 
obtained for the three subtypes (Wald test).  
In order to know to what extent the duration and/or extension of the disease may have affected our results, 
multinomial models were also used to quantify the effect of 25(OH)D according to: 1) time from diagnosis to 
sample extraction in cases (<30 days, 30-60 days, >60 days or unknown) and 2) stage at diagnosis (stage I, 
stage II, stages III and IV).  
Finally, possible effect modifications were contrasted by including interaction terms of 25(OH)D level 
(continuous) with each of the covariates in the final model. All analyses were performed using STATA/MP 
14.2 software.  
3. Results 
We initially selected 558 breast cancer cases and 558 controls, but 12 cases where excluded because they had 
initiated chemotherapy before blood extraction. Thus, the final sample cohort included 546 cases and 558 
controls. Table 1 describes both groups. Their mean age was 56 years, around 2/3 were postmenopausal and 
97% were Caucasian. Cases had more relatives with breast cancer and higher prevalence of previous biopsies, 
while tended to be less educated and have darker skin color than controls. Cases had a lower concentration of 
25(OH)D, even though the percentage of samples collected in summer and fall (seasons where Vit D 
concentrations are higher) was greater in this group (Table 1). 
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Table 2 shows the distribution of 25(OH)D levels according to socioeconomic, reproductive and life style 
characteristics in the control group. Apart from seasonal and geographical variations, the concentration of 
25(OH)D decreased with age and BMI. It was lower in non-Caucasians and higher in women with 
hypercholesterolemia and in those who had used HRT.  
 
The association of 25(OH)D levels with breast cancer risk is shown in Table 3. Model 1 included, apart from 
the geographical area, the other matching variables: age and BMI. Model 2 added menopausal status and day 
of sample extraction. Model 3a added to Model 2 the following confounders: educational level, ethnicity, age 
at first full term delivery, family history of breast cancer, previous breast biopsies, physical activity, 
hypercholesterolemia, HRT use and skin color. Finally, Model 3b further adjusted for the following dietary 
factors: total energy intake, calcium intake and alcohol intake to test their possible role as confounders. In all 
models, a clear protective effect is seen, with ORs decreasing with increasing concentrations of 25(OH)D, with 
a dose-response trend highly significant (OR per 10 nmol/L= 0.88; 95%CI= 0.82-0.94). The protective effect, 
though, seems to level-off at the fourth quintile. According to the final model (model 3a), women in the two 
highest quintiles had a reduction of risk over 50% (ORQ4vsQ1= 0.40; 95%CI= 0.26-0.61; ORQ5vsQ1= 0.46; 
95%CI= 0.30-0.70).  
 
This apparent level-off is explained by the shape of the dose-response curve (Figure 1), that showed a clear 
and statistically significant departure from linearity (p value<0.001). Breast cancer risk clearly declined for 
concentrations between 30 and 70 nmol/L, and the risk seems to increase afterwards, though it should be noted 
that only 13% of controls and 10% of cases had concentrations over 70 nmol/L, and around 3% had levels 
greater than 90 nmol/L. For this reason, in subsequent subgroup analyses, we used tertiles of 25(OH)D and 
dose-response tests assumed a linear trend.  
 
 
 
Table 4 presents the results in pre and postmenopausal women (top) and according to breast cancer subtypes 
(medium rows) and stage at diagnosis (bottom). No clear differences were observed between pre and 
postmenopausal women (p-interaction=0.597). Regarding breast cancer subtypes, ER+/PR+ tumors and 
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HER2+ tumors presented similar effects (OR per 10 nmol/L= 0.89 and 0.88 respectively), but 25(OH)D 
seemed to be particularly protective against triple negative tumors (OR per 10 nmol/L= 0.64;  p-
heterogeneity=0.038), though this result is based on a reduced number of cases (36 breast cancer cases and 
558 controls. Regarding stage at diagnosis, only 5 cases had metastasis at diagnosis, so stages III and IV were 
combined in a single category. No differences in the effect of 25(OH)D were observed according to breast 
cancer stage (p-heterogeneity=0.706). 
 
Figure 2 plots the linear effect of 25(OH)D serum concentration on breast cancer risk (per 10 nmol/L) in 
subgroup analyses by categories of the following variables: age, education, menarche, age at first child, family 
history of breast cancer, previous biopsies, BMI, tobacco, physical activity, skin color, hypercholesterolemia, 
HRT use and season. No differences were seen across strata, and all interaction p-values were greater than 
0.30. 
 
Finally, we tested whether the mean 25(OH)D levels in cases differed according to the time elapsed between 
diagnosis and blood sampling. No differences were observed in 25(OH)D levels in cases sampled in the first 
15 days compared to those sampled in week 3rd and 4th after diagnosis (45.89 nmol/L and 45.96 nmol/L, p-
value=0.977). However, 25(OHD) level seemed to decrease after the first month of diagnosis (25(OH)D 
mean=41.75 nmol/L in women sampled in the second month; p-value=0.067; and 25(OH)D mean=40.95 
nmol/L in women sampled afterwards; p-value=0.109). Owing to these differences, a sensitivity analysis was 
conducted considering only breast cancer cases sampled in the first month (298 cases). The overall effect per 
10 nmol/L was slightly attenuated, though no different from that obtained using the whole sample (OR=0.92; 
95%CI=0.85-0.99; p-value=0.034). The corresponding OR for the second and third tertiles of 25(OH)D were 
0.63 (95%CI=0.44-0.92) and 0.49 (95%CI=0.32-0.73), respectively. The heterogeneity of effects according to 
breast cancer subtype was confirmed (p-heterogeneity=0.012). The OR per 10 nmol/L of 25(OH)D was 0.92 
for  ER+|PR+&HER2-  (95%CI=0.84-1.01), 1.00 for HER2+ tumors (95%CI= 0.85-1.17) and 0.53 for triple 
negative tumors (95%CI=0.36-0.78). These results are based on 205 ER+|PR cases, 43 HER2+ cases and 21 
triple negative tumors (see Supplemental Material, Table S1). 
 
4. Discussion 
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To our knowledge, this is the first study providing information on the association of 25(OH)D levels with 
breast cancer risk by pathologic subtype in Spain. Our results show a consistent protective effect with increase 
25(OH)D serum levels on breast cancer risk This effect is similar in pre and postmenopausal women, but, 
interestingly enough, it seems to be stronger for triple negative tumors. Even though the non-linear shape of 
the dose-response might suggest an increased risk in women at the upper extreme of the 25(OH)D range, very 
few women had concentrations over 90 nmol/L.  
 
Mean serum 25(OH) concentration in our study was similar to that reported in other European countries [18], 
similar to that detected in small studies carried out in different Spanish regions [8] and slightly lower than the 
concentration detected in larger Spanish studies, where the average levels fluctuated between 56 and 62 nmol/L 
[19-21]. The prevalence of vitamin D deficiency (<50nmol/L) in our study (55% in controls and 69% in BC 
cases) was higher than that reported among pre and post Mexican women (36%) [22], higher than the reported 
at European level (40%) [18], and also higher than that reported in other Spanish studies [19-21, 23], but much 
lower than that detected by Almirall et al. in 2010 [24] (80%) and Aguado et al. in 2000 [25] (87%) among 
postmenopausal Spanish women. 
 
Some meta-analyses have investigated the association between serum 25(OH)D levels and breast cancer risk 
reporting controversial results. Among those focused solely on prospective studies, two detected an inverse 
association only in postmenopausal women [26, 27], while the most recent reported a weak and nonsignificant 
inverse association [12]. Other meta-analyses that separated analysis for case-control and prospective studies 
found that the inverse association was restricted to case-control studies [11, 13]. However, Chen et al, in a 
meta-analysis of 11 nested case-control and retrospective studies and 10 case-control studies, suggested that 
higher blood vitamin D levels were associated with a significantly reduced risk of breast cancer [10]. 
 
The non-linear dose-response association detected in our study has been previously described by Bauer et al. 
[26]. In this study, 25(OH)D levels at or above 27 ng/mL (67.5 nmol/L) threshold were associated with a 12% 
lower risk of postmenopausal breast cancer per 5ng/mL increase in 25(OH)D. However, no further reductions 
in risk were observed above 35 ng/mL (87.5 nmol/L). In our study, these cut-off points were left-shifted (30 
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and 70 mmol/L, respectively), although it should be noted that serum 25(OH)D levels in our women were 
lower than those reported in this meta-analysis. 
 
In consonance with previous studies [28-31], women with triple negative breast cancer presented the lowest 
mean 25(OH)D serum concentration and therefore, high levels of vitamin D seemed to be particularly 
protective against this pathological subtype. Two previous epidemiological studies also found an inverse 
association between serum 25(OH)D concentrations and triple negative breast cancer risk [32, 33]. 
Approximately two-thirds of these tumors express VDR [34], and it has been demonstrated that ligand bound 
VDR inhibits the proliferation of triple negative breast cancer cell lines, inhibits the triple negative breast 
cancer stem-like cells, induces differentiation and attenuates metastatic potential [34-36]. Moreover, 
interesting studies revealed that calcitriol can stabilize DNA repair protein 53BP1 levels in tumor cells, 
contributing to reduce proliferation of breast cancer with the poorest prognosis [37, 38], and can also induce 
de novo E-cadherin expression by promoter demethylation in triple-negative breast cancer cells [39]. 
 
On the other hand, since calcitriol can suppress the expression of aromatase, reducing estrogen synthesis via 
direct and indirect pathways [36], most studies have found an inverse association mainly in postmenopausal 
women [26, 27]. Although we did not detect statistically significant differences between pre and 
postmenopausal women in our study, a stronger protective effect was observed in postmenopausal women.  
 
The major limitation of the present analysis is the possibility of reverse causation, a particular concern in case-
control studies. Since vitamin D levels were assessed after diagnosis, it may be possible that the progression 
of the disease or changes in patients’ lifestyle would have adversely affected 25(OH)D concentrations. In an 
attempt to minimize this bias a sensitivity analysis was also performed considering only breast cancer cases 
sampled in the first month after diagnosis (time in which the serum 25(OH)D concentrations were not altered 
in our participants), and results of this sub analysis were very similar to those obtained using the whole sample. 
This one-month time window is in agreement with the serum half-life of 25(OH)D, estimated approximately 
in 3 weeks [40]. Although prospective studies with serum 25(OH)D samples collected prior to diagnosis are 
preferred, optimal timing of vitamin D assessment is uncertain. There is previous evidence that follow-up 
periods after serum sampling should not be too long for breast cancer since it develops rapidly, concluding 
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that case–control studies of breast cancer incidence provide reliable results and should be used rather than 
nested case-control studies with samples taken many years before diagnosis [41, 42]. Another relevant issue is 
that the pre-existing local inflammatory lesions involved in the onset of the disease could have contributed to 
reducing serum 25(OH)D levels, mainly in the case of triple negative breast tumors [43]. However, there is 
previous evidence that vitamin D inhibits inflammation, suggesting the reverse, that is, reduced vitamin D 
levels might increase inflammation [3]. Another relevant issue in case-control studies is the potential of 
selection bias. This study attempted to recruit all cases with a first diagnosis of breast cancer in the selected 
health areas, ensuring that very few incident cases were missed, and general practitioner lists were used to 
select controls. On the other hand, despite having adjusted for the most established risk factors, residual 
confounding cannot be ruled out. However, those characteristics with a geographical distribution have been at 
least partly accounted for through the random effect province term included in our statistical analyses. Finally, 
we were limited by the small sample size when evaluating the association by stage at diagnosis and by 
pathologic breast cancer subtype, mainly in the case of triple negative tumors whose frequency is very low in 
our context [44]. Despite these limitations, to date, this is the largest epidemiological study conducted in Spain 
that analyzes the association between serum 25(OH)D levels and breast cancer risk by pathological subtype or 
stage at diagnosis. On the other hand, histologically confirmed cases and population controls were recruited in 
12 Spanish regions located throughout the Spanish geography, which allowed us to have a broad representation 
of the lifestyle and dietary habits that coexist in Spain. An important strength of our study is the use of BMI 
as a matching factor, since BMI affects both vitamin D serum levels and breast cancer risk in postmenopausal 
women. Finally, the LC-MS/MS method can be considered the gold standard for 25(OH)D determination, 
demonstrating better performance than other automated methods [45].  
 
5. Conclusions 
Our results confirm an inverse association between 25(OH)D serum levels and breast cancer risk, which was 
more pronounced in triple negative tumors. Public health and clinical strategies aimed at improving vitamin D 
levels would be desirable, taking into account the high proportion of women with inadequate concentrations 
of 25(OH)D. 
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Figure 1. Dose-response relationship between 25-hydroxyvitamin D levels and breast cancer risk. 
 
 
Abbreviations: BC. breast cancer; 25(OH)D, 25-hydroxyvitamin D. 
Adjusted for age, body mass index, menopausal status, day of sample extraction, educational level, 
ethnicity, age at first full term delivery, family history of breast cancer, previous breast biopsies, 
hypercholesterolemia, hormone replacement therapy use, skin color, and physical activity in the last 5 
years. Geographical area introduced as a random effect term. 
 
 
Figure 2. Breast cancer risk for every 10 nmol/L increase in serum 25-hydroxyvitamin D concentration 
according to women characteristics. 
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 Abbreviations: OR(95%CI), odds ratio an 95% confidence interval; BMI, body mass index; HRT, 
hormone replacement therapy. 
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Adjusted for age, body mass index, menopausal status, day of sample extraction, educational level, 
ethnicity, age at first full term delivery, family history of breast cancer, previous breast biopsies, 
hypercholesterolemia, hormone replacement therapy use, skin color and physical activity in the last 5 
years. Geographical area introduced as a random effect term. 
 
 
Table 1. Descriptive characteristics of breast cancer cases and controls. 
  Controls Cases p-valuea 
  (n=558) (n=546)   
Geographical region [n (%)]   0.996 
   Madrid 115 (20.6) 113 (20.7)  
   Barcelona 50 (9.0) 55 (10.1)  
   Navarra 54 (9.7) 46 (8.4)  
   Gipuzkoa 132 (23.7) 122 (22.3)  
   Leon 89 (16.0) 88 (16.1)  
   Asturias 40 (7.2) 44 (8.1)  
   Huelva 4 (0.7) 3 (0.6)  
   Cantabria 42 (7.5) 44 (8.1)  
   Valencia 9 (1.6) 8 (1.5)  
   Girona 23 (4.1) 23 (4.2)  
Age (y) (mean±SD) 56 ±12.0 56 ±11.7 0.541 
Ethnicity  [n (%)]   0.745 
  Caucasian 543 (97.3) 533 (97.6)  
  Other 15 ( 2.7) 13 ( 2.4)  
Educational level  [n (%)]   0.076 
   Less than primary school 66 (11.8) 76 (13.9)  
   Primary school completed 173 (31.0) 195 (35.7)  
   Secondary school  192 (34.4) 180 (33.0)  
   University graduate 127 (22.8) 95 (17.4)  
Body mass index (Kg/m2)  (mean±SD)    
  Premenopausal women 23.7±3.4 23.6±3.5 0.829 
  Postmenopausal women 26.3±4.1 26.6±4.5 0.480 
Age at menarche (y)  [n (%)]   0.740 
   <12 115 (20.6) 109 (20.0)  
   12-13 260 (46.6) 267 (48.9)  
   >=14 183 (32.8) 170 (31.1)  
Menopausal status  [n (%)]   0.347 
   Postmenopausal 200 (35.8) 181 (33.2)  
   Premenopausal 358 (64.2) 365 (66.8)  
Age at first birth (y) [n (%)]   0.889 
   <20 21 /4.8) 24 (5.5)  
   20-24 126 (28.5) 130 (20.8)  
   25-29 179 (40.5) 168 (38.5)  
   >=30 114 (25.8) 109 (25.0)  
   Unknown 2 (0.5) 5 (1.2)  
Number of children  [n (%)]   0.608 
   None 116 (20.8) 110 (20.1)  
   1-2 318 (57.0) 325 (59.5)  
   3-4 100 (17.9) 95 (17.4)  
   >4 24 ( 4.3) 16 ( 2.9)  
Family history of breast cancer  [n (%)]   <0.001 
   No 483 (86.6) 412 (75.5)  
   Second degree only 32 ( 5.7) 53 ( 9.7)  
   1 First degree 40 ( 7.2) 73 (13.4)  
   > 1 First degree 3 ( 0.5) 8 ( 1.5)  
Previous biopsies  [n (%)]   <0.001 
   No 547 (98.0) 511 (93.6)  
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   Yes 11 ( 2.0) 35 ( 6.4)  
Tobacco consumption  [n (%)]   0.813 
   No 298 (53.4) 296 (54.2)  
   Exsmoker 116 (20.8) 118 (21.6)  
   Current smoker 144 (25.8) 132 (24.2)  
Physical activity (MET-h/week)  [n (%)]   0.201 
   No 214 (38.4) 237 (43.4)  
   < 8  76 (13.6) 56 (10.3)  
   8-15.9 79 (14.2) 71 (13.0)  
   >=16  189 (33.9) 182 (33.3)  
Skin color  [n (%)]   0.094 
   Pale white 42 (7.5) 31 (5.7)  
   White 240 /43.0) 239 (43.8)  
   Light brown 189 (33.9) 208 (38.1)  
   Dark brown 83 /14,9) 68 (12.5)  
   Black 4 (0.2) 0 (0.0)  
Eye color  [n (%)]   0.707 
   Dark brown 312 (55.9) 296 (54.2)  
   Light brown or green 169 (30.3) 178 (32.6)  
   Blue or gray 76 (13.6) 71 (13.0)  
   Unknown 1 (0.2) 1 (0.2)  
Hipercolesterolemia  [n (%)]   0.344 
   No  399 (71.5)  411 (75.3)  
   Yes, not treated  116 (20.8) 101 (18.5)  
  Treated with statins 43 ( 7.7) 34 ( 6.2)  
Use of corticoids  [n (%)]   0.171 
   No  399 (71.5) 483 (88.5)  
   Yes 58 (10.4) 45 ( 8.2)  
   Unknown 32 ( 5.7) 18 ( 3.3)  
Hormone replacement therapy use  [n (%)]   0.892 
   Never 497 (89.1) 490 (89.7)  
   <= 5 years 43 ( 7.7) 28 (5.1)  
   > 5 years 11 (2.0) 10 (1.8)  
   Unknown 18 ( 3.2) 18 (3.3)  
Alcohol consumption (g/day)  [n (%)]   0.018 
   No 195 (34.9)  179 (32.8)  
   < 15  256 (45.9)  235 (43.0)  
   15-29.9  38 ( 6.8)  40 ( 7.3)  
   >=30  15 ( 2.7)  36 ( 6.6)  
   Unknown b  54 ( 9.7)  56 (10.3)  
Total energy intake (kcals) (mean±SD) b 1766.9±552.0 1826.6±516.9 0.068 
Total calcium intake (g/day) (mean±SD) b 922.7±303.3 930.5±328.5 0.698 
Total vitamin D intake (µg/day) (mean±SD) b 2.5±1.2 2.6±1.4 0.045 
Vitamin D (nmol/L) (mean±SD)    
   25-hydroxyvitamin D 48.2±19.9 43.6±22.3 <0.001 
Season  [n (%)]   0.010 
   Spring 217 (38.9) 174 (31.9)  
   Summer 74 (13.3) 106 (19.4)  
   Fall 109 (19.5) 120 (22.0)  
   Winter 158 (28.3) 146 (26.7)   
a p-values were computed with the chi-square test and t-test. 
b Participants who did not answer the food frequency questionnaire (54 controls and 56 cases) do not 
have information. 
Table 2 shows the distribution of 25(OH)D levels according to socioeconomic, reproductive and life 
style characteristics in the control group. Apart from seasonal and geographical variations, the 
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concentration of 25(OH)D decreased with age and BMI. It was lower in non-Caucasians and higher in 
women with hypercholesterolemia and in those who had used HRT.  
 
Table 2. Variables influencing 25-hydroxyvitamin D levels. Mean levels according to baseline 
characteristics in the control group. 
    25(OH)Da   
Variable N Mean P25-P75 p-valueb 
Geographical region    0.047 
   Madrid 115 52.48 40.90- 64.50  
   Barcelona 50 46.02 28.80- 57.20  
   Navarra 54 45.10 28.20- 61.00  
   Gipuzkoa 132 49.51 36.80- 59.75  
   Leon 89 43.27 31.30- 52.90  
   Asturias 40 49.24 34.25- 61.85  
   Huelva 4 57.05 41.80- 72.30  
   Cantabria 42 46.41 32.50- 57.60  
   Valencia 9 54.88 44.70- 69.10  
   Girona 23 43.31 27.10- 54.10  
Age (y)    0.025 
   <40 35 53.86 31.10- 65.40  
   40-49 140 44.57 29.80- 55.35  
   50-59 164 49.43 36.70- 59.75  
   60-69 138 50.02 35.00- 63.70  
   >=70 81 45.20 29.60- 58.90  
Ethnicity    <0.001 
  Caucasian 543 48.60 34.40- 61.40  
   Other 15 26.89 20.70- 30.40  
Educational level    0.882 
   Less than primary school 66 46.45 36.00- 58.60  
   Primary school completed 173 48.00 33.30- 60.00  
   Secondary school  192 47.99 31.30- 61.90  
   University graduate 127 48.90 34.50- 62.00  
Body mass index (Kg/m2)    0.024 
   <25 295 49.39 34.00- 62.70  
   25-29.9 187 48.13 33.30- 59.70  
   >=30  76 42.44 27.15- 53.65  
Age at menarche (y)    0.212 
   <12 115 45.35 29.30- 57.30  
   12-13 260 48.17 32.85- 61.00  
   >=14 183 49.49 34.40- 62.00  
Menopausal status    0.093 
   Postmenopausal 358 49.08 36.50- 61.90  
   Premenopausal 200 46.13 29.80- 57.45  
Age at first birth (y)    0.708 
   <20 21 44.07 25.80- 56.90  
   20-24 126 48.74 34.80- 60.60  
   25-29 179 47.70 31.90- 60.00  
   >=30 114 49.05 35.20- 61.90  
Number of children    0.324 
   None 116 47.52 31.25- 62.15  
   1-2 318 48.56 34.00- 61.50  
   3-4 100 48.58 36.35- 60.70  
   >4 24 40.90 27.30- 54.40  
Family history of breast cancer    0.742 
   No 483 48.26 32.80- 61.20  
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   Second degree only 32 44.40 33.85- 56.30  
   1 First degree 40 48.28 30.50- 61.50  
   > 1 First degree 3 44.33 17.60- 63.70  
Previous biopsies    0.137 
   No 547 47.84 32.50- 60.80  
   Yes 11 56.84 50.60- 73.80  
Tobacco consumption    0.155 
   No 298 47.79 32.50- 60.60  
   Exsmoker 116 50.91 35.25- 63.55  
   Current smoker 144 46.18 32.00- 57.00  
Physical activity (MET-h/week)     0.492 
   No 214 46.36 31.30- 58.60  
   < 8 76 49.08 34.60- 61.40  
   8-15.9 79 48.98 37.70- 61.10  
   >=16 189 49.06 31.90- 62.50  
Skin color    0.087 
   Pale white 42 52.18 41.20- 61.50  
   White 240 46.41 31.65- 58.50  
   Light brown 189 48.61 34.00- 62.70  
   Dark brown 83 50.13 31.50- 62.50  
   Black 4 29.30 15.40- 43.20  
Eye color    0.493 
   Dark brown 312 47.13 31.60- 59.75  
   Light brown or green 169 49.33 35.00- 61.90  
   Blue or gray 76 48.58 33.85- 61.20  
Hipercolesterolemia    0.058 
   No 399 46.79 31.60- 58.70   
   Yes, not treated 116 51.66 37.55- 63.70   
  Treated with statins 43 49.55 36.80- 60.90  
Use of corticoids    0.582 
   No 468 48.04 32.50- 61.05  
   Yes 58 49.57 34.50- 63.10  
Hormone replacement therapy use   0.042 
   Never 497 47.19 31.70- 59.80  
   <= 5 years 32 52.27 39.15- 62.25  
   > 5 years 11 60.11 46.80- 70.30  
Alcohol consumption (g/day)    0.407 
   No 195 47.63 33.20- 58.10  
    < 15 256 48.61 33.45- 61.20   
   15-29.9 38 50.84  38.90- 62.70   
   >=30  15 41.10  18.70- 54.50   
Energy intake ( kcals)    0.263 
   <1385 126 48.11 30.40- 60.90  
   1385-1700 126 46.33 34.60- 56.60  
   1701-2070 126 51.00 37.60- 62.60   
   >2070 126 47.25 31.70- 61.00  
Calcium intake (g/day)    0.080 
   <720 126 44.72 30.60- 57.10   
   720-895 126 47.55  31.80- 60.90   
   896-1126 126 49.91 36.50- 60.20   
   >1126 126 50.51  33.30- 64.70  
Vitamin D intake  (µg/day)    0.650 
   < 1.531 126 48.91 31.80- 62.70  
   1.531-2.420 126 47.10 31.60- 59.70  
   2.421-3.135 126 47.06 34.00- 58.90  
   > 3.135 126 49.63  35.80- 61.30   
Season    <0.001 
   Spring 217 44.48 30.00- 56.50  
   Summer 74 54.76 40.60- 67.30  
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   Fall 109 51.42 37.40- 64.20  
   Winter 158 47.38 31.90- 61.50   
a 25(OH)D levels in nmol/L 
b p-values were computed with  t-test. 
 
 
 
 
Table 3. Association between 25-hydroxyvitamin D levels and breast cancer risk. 
  
Cont
rols 
Case
s MODEL 1 a   MODEL 2 b   MODEL 3a c   MODEL 3b d 
  
(n=5
58) 
(n=5
46) 
OR(95%CI
) 
p-
valu
e  
OR(95%CI
) 
p-
valu
e  
OR(95%CI
) 
p-
valu
e  
OR(95%CI
) 
p-
valu
e 
25(OH)D 
(nmol/L)              
  <=29.98 111 153 1.00   1.00   1.00   1.00  
  ]29.98-
41.74] 112 149 
0.97(0.68, 
1.37) 
0.76
8  
0.90(0.63, 
1.28) 
0.56
2  
0.96(0.66, 
1.39) 
0.81
7  
0.96(0.64, 
1.42) 
0.82
3 
  ]41.74-
52.70] 113 97 
0.63(0.43, 
0.90) 
0.00
9  
0.56(0.38, 
0.81) 
0.00
3  
0.55(0.37, 
0.82) 
0.00
4  
0.61(0.40, 
0.93) 
0.02
2 
  ]52.70-
63.70]  112 68 
0.44(0.30, 
0.65) 
<0.0
01  
0.39(0.26, 
0.58) 
<0.0
01  
0.40(0.26, 
0.61) 
<0.0
01  
0.41(0.26, 
0.64) 
<0.0
01 
  >63.70 110 79 
0.52(0.36, 
0.77) 
0.00
1  
0.43(0.29, 
0.64) 
<0.0
01  
0.46(0.30, 
0.70) 
<0.0
01  
0.50(0.32, 
0.79) 
0.00
3 
  Trend per 10 
nmol/L     
0.90(0.85, 
0.96) 
0.00
1   
0.88(0.83, 
0.94) 
<0.0
01   
0.88(0.82, 
0.94) 
<0.0
01   
0.89(0.83, 
0.95) 
0.00
1 
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; OR(95%CI), odds ratio an 95% confidence interval. 
a Adjusted for age and body mass index. Geographical area introduced as a random effect term. 
b Additionally adjusted for menopausal status and day of sample extraction. 
c Additionally adjusted for educational level, ethnicity, age at first full term delivery, family history of 
breast cancer, previous breast biopsies, hypercholesterolemia, hormone replacement therapy use, skin 
color, and physical activity in the last 5 years. 
d Additionally adjusted for total energy intake, calcium intake and alcohol intake (54 controls and 56 
cases without information on diet are excluded). 
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Table 4. Association between 25-hydroxyvitamin D levels and breast cancer risk by menopausal status, 
tumor subtype and stage at diagnosis. 
MENOPAU
SAL 
STATUS OVERALL   PREMENOPAUSAL   POSTMENOPAUSAL     
25(OH)D 
nmol/L 
Control
s   Cases 
OR 
(95% 
CI)a 
p-
val
ue  
Control
s Cases 
OR 
(95% 
CI)a 
p-
val
ue  Controls Cases 
OR 
(95% 
CI)a 
p-
val
ue  
p-
int 
Mean (95% 
CI) 
48.3 
(45.9, 
50.7)  
43.2 
(40.8, 
45.6)    
47.2 
(43.6, 
50.8) 
42.2 
(38.5, 
46.0)    
48.9 
(46.2-
51.5) 
43.5 
(40.9-
46.1)     
<=37.65 184  260 1.00   80 83 1.00   104 177 1.00    
]37.65-
55.2] 187  158 
0.56 
(0.41, 
0.76) 
<0.
00
1  61 53 
0.79 
(0.46, 
1.34) 
0.3
74  126 105 
0.44 
(0.30, 
0.65) 
<0.
00
1   
>55.2 187  128 
0.44 
(0.31, 
0.61) 
<0.
00
1  59 45 
0.54 
(0.30, 
0.98) 
0.0
43  128 83 
0.36 
(0.24, 
0.54) 
<0.
00
1   
trend per 
10 nmol/L    
0.88 
(0.82, 
0.94) 
<0.
00
1    
0.85 
(0.75, 
0.97) 
0.0
12    
0.88 
(0.80, 
0.95) 
0.0
01  
0.5
97 
                  
TUMOR 
SUBTYPEb     ER+/PR+ & HER2-   HER2+   TRIPLE NEGATIVE     
25(OH)D 
nmol/L 
Control
s  Cases 
OR 
(95% 
CI)a 
p-
val
ue  Cases 
OR 
(95% 
CI)a 
p-
val
ue  Cases 
OR 
(95% 
CI)a 
p-
val
ue  
p-
het 
Mean (95% 
CI) 
48.3 
(45.9, 
50.7)  
43.5 
(40.9, 
46.2)    43.2 (38.6, 47.9)    35.4 (28.6, 42.2)     
<=37.65 184  176 1.00   38 1.00   21 1.00    
]37.65-
55.2] 187  104 
0.57 
(0.40, 
0.80) 
0.0
01  27 
0.70 
(0.39, 
1.26) 
0.2
31  11 
0.46 
(0.19, 
1.08) 
0.0
73   
>55.2 187  85 
0.43 
(0.29, 
0.63) 
<0.
00
1  19 
0.49 
(0.25, 
0.97) 
0.0
40  4 
0.16 
(0.05, 
0.51) 
0.0
02   
trend per 
10 nmol/L    
0.89 
(0.82, 
0.96) 
0.0
02    
0.88 
(0.77, 
1.01) 
0.0
71    
0.64 
(0.49, 
0.82) 
<0.
00
1  
0.0
38 
                  
STAGE AT 
DIAGNOSISc   Stage I   Stage II   Stage III-IV     
25(OH)D 
nmol/L 
Control
s  Cases 
OR 
(95% 
CI)a 
p-
val
ue  Cases 
OR 
(95% 
CI)a 
p-
val
ue  Cases 
OR 
(95% 
CI)a 
p-
val
ue  
p-
het 
Mean (95% 
CI) 
48.3 
(45.9, 
50.7)  
43.0 
(39.8, 
46.2)    42.5 (39.2, 45.8)    40.8 (35.2, 46.3)     
<=37.65 184  96 1.00   91 1.00   34 1.00    
]37.65-
55.2] 187  62 
0.55 
(0.36, 
0.84) 
0.0
06  53 
0.55 
(0.36, 
0.84) 
0.0
06  10 
0.31 
(0.14, 
0.68) 
0.0
03   
>55.2 187  58 
0.43 
(0.28, 
0.68) 
<0.
00
1  40 
0.37 
(0.23, 
0.59) 
<0.
00
1  12 
0.31 
(0.14, 
0.89) 
0.0
04   
trend per 
10 nmol/L       
0.86 
(0.78, 
0.95) 
0.0
02       
0.85 
(0.77, 
0.93) 
0.0
01       
0.79 
(0.66, 
0.95) 
0.0
11   
0.7
06 
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; OR(95%CI), odds ratio an 95% confidence interval; 
p-int, p-value for interaction; p-het, p-value for heterogeneity; ER+/PR+ & HER2-, estrogen receptor 
positive and/or progesterone receptor positive tumors with human epidermal growth factor receptor 2 
negative; HER2+, human epidermal growth factor receptor 2 positive tumors. 
a Adjusted for  age, body mass index, menopausal status, day of sample extraction, educational level, 
ethnicity, age at first full term delivery, family history of breast cancer, previous breast biopsies, 
hypercholesterolemia, hormone replacement therapy use, skin color, and physical activity in the last 5 
years. Geographical area introduced as a random effect term. 
b Sixty-one breast cancer cases could not be classified. 
c Ninety breast cancer cases could not be classified. 
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Table S1. Association between 25-hydroxyvitamin D levels and breast cancer risk considering only 
cases sampled in the first month after diagnosis. 
MENOPAUSAL STATUS OVERALL   PREMENOPAUSAL   POSTMENOPAUSAL     
25(OH)D nmol/L Controls   Cases OR (95% CI)a p-value  Controls Cases OR (95% CI)a p-value  Controls Cases OR (95% CI)a p-value  p-int 
<=37.65 184  130 1.00   80 45 1.00   104 85 1.00    
]37.65-55.2] 187  89 0.63 (0.44-0.92) 0.015  61 28 0.69 (0.36-1.31) 0.255  126 61 0.57 (0.36-0.90) 0.016   
>55.2 187  79 0.49 (0.32-0.73) <0.001  59 31 0.60 (0.30-1.22) 0.156  128 48 0.41 (0.25-0.68) 0.001   
trend per 10 nmol/L    0.92 (0.85-0.99) 0.034   0.89 (0.77-1.03) 0.117    0.92 (0.84-1.02) 0.107  0.597 
                  
TUMOR SUBTYPEb     ER+/PR+ & HER2-   HER2+   TRIPLE NEGATIVE     
25(OH)D nmol/L Controls  Cases OR (95% CI)a p-value  Cases OR (95% CI)a p-value  Cases OR (95% CI)a p-value  p-het 
<=37.65 184  88 1.00   17 1.00   15 1.00    
]37.65-55.2] 187  63 0.68 (0.45-1.04) 0.073  12 0.70 (0.31-1.62) 0.407  5 0.23 (0.07-0.81) 0.023   
>55.2 187  54 0.50 (0.31-0.79) 0.003  14 0.69 (0.29-1.65) 0.401  1 0.04 (0.00-0.36) 0.004   
trend per 10 nmol/L       0.92 (0.84-1.01) 0.081     1.00 (0.85-1.17) 0.959     0.53 (0.36-0.78) 0.001   0.012 
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; OR(95%CI), odds ratio an 95% confidence interval; 
p-int, p-value for interaction; p-het, p-value for heterogeneity; ER+/PR+ & HER2-, estrogen receptor 
positive and/or progesterone receptor positive tumors with human epidermal growth factor receptor 2 
negative; HER2+, human epidermal growth factor receptor 2 positive tumors. 
a Adjusted for  age, body mass index, menopausal status, day of sample extraction, educational level, 
ethnicity, age at first full term delivery, family history of breast cancer, previous breast biopsies, 
hypercholesterolemia, hormone replacement therapy use, skin color, and physical activity in the last 5 
years. Geographical area introduced as a random effect term. 
b Twenty nine breast cancer cases could not be classified. 
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